Fused Pyridine Derivatives as Selective PI3K Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for various human ailments such as autoimmune, inflammatory, cardiovascular, neurodegenerative, metabolic, oncological, and ophthalmic conditions lack effective PI3K inhibitors, particularly with selective affinity for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ isoforms.
Innovation Solution
Development of fused pyridine derivatives as potent and selective inhibitors of PI3K enzymes, with specific structural formulas that exhibit high binding affinity and selective affinity for human PI3K isoforms, offering potential therapeutic benefits across multiple disease conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing PI3K inhibitors are used, then PI3K enzyme activity is inhibited, but selective affinity for specific PI3K isoforms is insufficient
Solution Approach 1:
The patent applies local quality by introducing specific heteroatomic substituents (nitrogen-containing groups like pyridinyl, pyrimidinyl, triazinyl) at defined positions (R1, R2, or R3) on the pyridine ring system. These localized chemical modifications create isoform-specific interactions with the PI3K enzyme active site, enabling selective binding to particular isoforms (α, β, γ, or δ) while maintaining inhibitory activity. The substitution patterns create distinct molecular recognition sites that differentiate between isoforms.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the pyridine derivative molecules, specifically the type of heteroatomic substituent, its position on the ring system, and its steric and electronic properties. This creates a series of compounds with different binding characteristics, allowing optimization of selective affinity for specific isoforms while maintaining effective inhibition across the PI3K enzyme family.
2Measurement precision
If fused pyridine derivatives with high binding affinity are developed, then selective affinity for PI3K isoforms is improved, but structural complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: the core pyridine ring system providing the basic binding framework, and separate heteroatomic substituent groups (pyridinyl, pyrimidinyl, triazinyl, etc.) that provide isoform-specific affinity. This modular approach allows independent optimization of each segment's contribution to binding affinity while maintaining overall structural manageability and enabling systematic exploration of the chemical space.
Data Source
AI summary
A series of heteroaryl-substituted fused pyridine derivatives, in particular heteroaryl-substituted thieno[3,2-6]pyridine derivatives, being selective inhibitors of PO kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.